Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors

Biomarkers

Volumn 13, Issue 6, 2008, Pages 579-596

  Xiao, Zhan ^a   Xue, John ^a   Gu, Wen Zhen ^a   Bui, Mai ^a   Li, Gaoquan ^a   Tao, Zhi Fu ^a   Lin, Nan Horng ^a   Sowin, Thomas ^a   Zhang, Haiying ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Biomarker; Cell cycle checkpoints; Chemotherapeutics; Chk1; Cyclin B1; Mitotic catastrophe; siRNA

Indexed keywords

A 776574; BIOLOGICAL MARKER; CAMPTOTHECIN; CHECKPOINT KINASE 1 INHIBITOR; CYCLIN B1; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; IRINOTECAN; PROTEIN INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CHROMOSOME CONDENSATION; CLINICAL TRIAL; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; MALE; MITOSIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PREDICTOR VARIABLE; PROTEIN EXPRESSION; PROTEIN STRUCTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOLOGICAL MARKERS; CELL PROLIFERATION; CYCLIN B; DNA TOPOISOMERASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GENE THERAPY; HELA CELLS; HISTONES; HUMANS; MALE; MICE; MICE, SCID; MITOSIS; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 53349108783     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500802063240     Document Type: Article

References (24)

1. Bartek, J. and Lukas, J. (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 3, pp. 421-429.
2. Booth, B. and Zemmel, R. (2004) Opinion/outlook: Prospects for productivity. Nature Reviews Drug Discovery, 3, pp. 451-456.
3. Busby, EC, Leistritz, DF, Abraham, RT, Karnitz, LM and Sarkaria, JN. (2000) The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Research, 60, pp. 2108-2112.
4. Chen, Z., Xiao, Z., Chen, J., Ng, SC, Sowin, T., Sham, H., Rosenberg, S., Fesik, S. and Zhang, H. (2003) Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Molecular Cancer Therapeutics, 2, pp. 543-548.
5. Chen, Z., Xiao, Z., Gu, WZ, Xue, J., Bui, MH, Kovar, P., Li, G., Wang, G., Tao, ZF, Tong, Y., Lin, NH, Sham, HL, Wang, JY, Sowin, TJ, Rosenberg, SH and Zhang, H. (2006) Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. International Journal of Cancer, 119, pp. 2784-2794.
6. Eastman, A., Kohn, EA, Brown, MK, Rathman, J., Livingstone, M., Blank, DH and Gribble, GW. (2002) A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: Similarities and differences to the cell cycle checkpoint abrogator UCN-01. Molecular Cancer Therapeutics, 1, pp. 1067-1078.
7. Edmunds, RC III, Ma, PC and Tanio, CP. (2001) Splicing a cost squeeze into the genomics revolution. McKinsey Quarterly, 2, pp. 15-18.
8. Fesik, SW. (2000) Insights into programmed cell death through structural biology. Cell, 103, pp. 273-282.
9. Frank, R. and Hargreaves, R. (2003) Clinical biomarkers in drug discovery and development. Nature Reviews Drug Discovery, 2, pp. 566-580.
10. Hendry, JH and West, CM. (1997) Apoptosis and mitotic cell death: Their relative contributions to normal-tissue and tumor radiation response. International Journal of Radiation Biology, 71, pp. 709-719.
11. Johnson, DG and Walker, CL. (1999) Cyclins and cell cycle checkpoints. Annual Review of Pharmacology and Toxicology, 39, pp. 295-312.
12. Koniaras, K., Cuddihy, AR, Christopoulos, H., Hogg, A. and O'Connell, MJ. (2001) Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene, 20, pp. 7453-7463.
13. Pascreau, G., Arlot-Bonnemains, Y. and Prigent, C. (2003) Phosphorylation of histone and histone-like proteins by aurora kinases during mitosis. Progress in Cell Cycle Research, 5, pp. 369-374.
14. Prigent, C. and Dimitrov, S. (2003) Phosphorylation of serine 10 in histone H3, what for?. Journal of Cell Science, 116, pp. 3677-3685.
15. Roninson, IB, Broude, EV and Chang, BD. (2001) If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resistance Updates, 4, pp. 303-313.
16. Strasser, A., O'Connor, L. and Dixit, VM. (2000) Apoptosis signaling. Annual Review of Biochemistry, 69, pp. 217-245.
17. Walworth, NC. (2000) Cell-cycle checkpoint kinases: Checking in on the cell cycle. Current Opinion in Cell Biology, 12, pp. 697-704.
18. Wang, L., Sullivan, GM, Hexamer, LA, Hasvold, LA, Thalji, R., Przytulinska, M., Tao, ZF, Li, G., Chen, Z., Xiao, Z. and Gu, WZ (2007) Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors. Journal of Medicinal Chemistry, 50, pp. 4162-4176.
19. Wang, A., Yoshimi, N., Ino, N., Tanaka, T. and Mori, H. (1997) Overexpression of cyclin B1 in human colorectal cancers. Journal of Cancer Research & Clinical Oncology, 123, pp. 124-127.
20. Xiao, Z., Chen, Z., Gunasekera, AH, Sowin, TJ, Rosenberg, SH, Fesik, S. and Zhang, H. (2003) Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. Journal of Biological Chemistry, 278, pp. 21767-21773.
21. Xiao, Z., Xue, J., Sowin, T., Rosenberg, S. and Zhang, H. (2004) A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene, 24, pp. 1403-1411.
22. Zhao, H., Watkins, JL and Piwnica-Worms, H. (2002) Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proceedings of the National Academy of Sciences U S A, 99, pp. 14795-14800.
23. Zhou, BB and Bartek, J. (2004) Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nature Reviews Cancer, 4, pp. 216-225.
24. Zhou, BB and Sausville, EA. (2003) Drug discovery targeting Chk1 and Chk2 kinases. Progress in Cell Cycle Research, 5, pp. 413-421.